Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial
- ONPATTRO„¢ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus
Third Quarter Conference Call and Webcast Scheduled Today at 4:30 PM ET
WARMINSTER, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus...